GlassScriptPhysician profile
Tyneah Morris
NPI 1184250755
$9,698.27
in general payments reported to CMS, 2019-2025
23 companies · $1,646 in 2025
The $1,646 reported for 2025 was more than what 89% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $938 · 2022: $1,411 · 2023: $2,432 · 2024: $3,271 · 2025: $1,646.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,349.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,348.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,325.36 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $1,737.58 | 2021-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Teva Pharmaceuticals USA, INC. | $1,245.52 | 2021-2025 | Austedo Xr, Uzedy, Austedo |
| Vanda Pharmaceuticals INC. | $986.47 | 2023-2025 | Fanapt, Hetlioz |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $696.04 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $632.43 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Axsome Therapeutics, INC. | $453.92 | 2023-2025 | Auvelity, Sunosi |
| Alkermes, INC. | $290.81 | 2022-2025 | Lybalvi, Aristada, Vivitrol |
| Tempus Ai, INC | $206.48 | 2024 | |
| Idorsia Pharmaceuticals US INC | $195.28 | 2023-2024 | Quviviq |
| Ironshore Pharmaceuticals INC. | $172.57 | 2022 | |
| Lundbeck LLC | $155.00 | 2022-2025 | Rexulti, Abilify Maintena |
| Corium, LLC | $134.26 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $121.84 | 2024 | Cobenfy |
| Tg Therapeutics, INC. | $107.94 | 2024 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $46.26 | 2021 | |
| Noven Therapeutics, LLC | $33.25 | 2023-2024 | Secuado |
| Biogen, INC. | $32.52 | 2024 | |
| Neurocrine Biosciences, INC. | $32.52 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $28.94 | 2022-2024 | Trintellix |
| Almatica Pharma LLC | $23.60 | 2024 | Loreev Xr |
| Supernus Pharmaceuticals, INC. | $21.60 | 2025 | Qelbree |
| Tris Pharma INC | $18.08 | 2025 | Dyanavel Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tyneah Morris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.